Impedimed (ASX:IPD) Net Income (Continuing Operations): A$-24.37 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Impedimed Net Income (Continuing Operations)?

Impedimed ASX:IPD Net Income (Continuing Operations) is A$-24.37 Mil as of Dec. 2025. The stock has 6 warning signs investors should review.

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Impedimed's Net Income (Continuing Operations) for the six months ended in Dec. 2025 was A$-12.28 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-24.37 Mil.

Impedimed  (ASX:IPD) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Impedimed Net Income (Continuing Operations) Related Terms

Impedimed Net Income (Continuing Operations) Historical Data

* Premium members only.

The historical data trend for Impedimed's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Impedimed Net Income (Continuing Operations) Chart

Impedimed Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Net Income (Continuing Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -20.71 -19.87 -20.52 -19.79 -23.24

Impedimed Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.72 -10.07 -11.15 -12.09 -12.28

Impedimed Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-24.37 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income (Continuing Operations) of A$-24.37 Mil mean?
Impedimed (ASX:IPD) has a Net Income (Continuing Operations) of A$-24.37 Mil as of Dec. 2025. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Impedimed and its competitors.
Is Impedimed's Net Income (Continuing Operations) too high?
Impedimed's current Net Income (Continuing Operations) is A$-24.37 Mil.
How does Impedimed's Net Income (Continuing Operations) compare to ABT and SYK?
Impedimed's Net Income (Continuing Operations) of A$-24.37 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income (Continuing Operations) for a Medical Devices & Instruments company?
A good Net Income (Continuing Operations) depends on the Medical Devices & Instruments industry context. However, Net Income (Continuing Operations) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income (Continuing Operations) mean?
A high Net Income (Continuing Operations) can signal that a stock is expensive relative to its fundamentals. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Impedimed and its competitors. Impedimed's current Net Income (Continuing Operations) is A$-24.37 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Impedimed stock overvalued right now?
Impedimed (ASX:IPD) has a current Net Income (Continuing Operations) of A$-24.37 Mil. The current Net Income (Continuing Operations) is A$-24.37 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income (Continuing Operations) calculated?
Net Income (Continuing Operations) is calculated from a company's financial statements. For Impedimed (ASX:IPD), the current Net Income (Continuing Operations) is A$-24.37 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Impedimed Business Description

Other Exchanges IPDQF:USA
Address 5900 Pasteur Court, Suite 125, Carlsbad, CA, USA, 92008
Impedimed Ltd, together with its subsidiaries, operates in the medical devices space. The company is based in Australia and operates globally, and it generates the majority of its revenue in North America. It is engaged in developing, manufacturing, and distributing noninvasive medical devices. The company offers products that are typically used to assess and monitor lymphedema and heart failure, as well as to measure the tissue composition and fluid status of the patients. The company also offers a cloud-based digital platform (branded as SOZO) to manage patient data. The company recognises revenue from the stand-alone sale of Legacy Devices and Consumables, the Sale of SOZO Devices, and Software Subscription Services.